This is a first-in-human, randomized, double-blind, placebo-controlled clinical study to evaluate the Safety and Tolerability of SPOT-mRNA01 injection in healthy adult volunteers.
None
Any transient or chronic skin condition, disorder, or infection within 20 cm of the target areas before treatment that, in the opinion of the investigator, may confound study results.
History of laser treatment or chemical peels or any cosmetic anti-aging treatments to the target areas within six months of the study treatment.
History of surgical procedures to target areas, including removal of benign or malignant skin cancers that, in the opinion of the investigator, may confound study results.
Participant with a history of heavy smoking, alcohol or drug abuse or steroid treatment.
SIPO Biotechnology Co. Ltd.
Lead sponsor
Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University
Collaborator